Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Mar;108(3):651–657. doi: 10.1111/j.1476-5381.1993.tb12856.x

Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats.

P Madeddu 1, V Anania 1, P P Parpaglia 1, M P Demontis 1, M V Varoni 1, M C Fattaccio 1, N Glorioso 1
PMCID: PMC1908027  PMID: 8385532

Abstract

1. The contribution of endogenous kinins to the regulation of blood pressure and renal function of Wistar rats was evaluated by use of the new B2-receptor antagonist, Hoe 140, (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin). 2. Neither Hoe 140 (4 micrograms h-1 s.c., for 6 weeks), nor vehicle altered systolic blood pressure (SBP, tail-cuff plethysmography) or renal function in rats, under normal conditions. 3. Chronic administration of deoxycorticosterone (DOC, 25 mg kg-1 s.c., weekly) increased SBP slightly only after 6 weeks (from 124 +/- 2 to 133 +/- 3 mmHg, P < 0.05). An earlier and greater rise in SBP (P < 0.01) occurred when DOC was combined with chronic infusion of Hoe 140 (from 125 +/- 1 to 154 +/- 3, P < 0.01). The hypertensive effect of Hoe 140 was confirmed by direct measurement of mean blood pressure (143 +/- 2 vs 122 +/- 2 mmHg in controls, P < 0.01). 4. DOC caused an initial fall, followed by a transitory increase in urinary volume and sodium excretion; thereafter, both parameters returned to baseline. The initial antidiuretic and antinatriuretic effects were enhanced by Hoe 140 (P < 0.05). 5. Urinary prostaglandin E2 excretion was increased by DOC (from 106 +/- 3 to 153 +/- 4 ng 24 h-1, P < 0.01) and this effect was prevented by Hoe 140 (from 95 +/- 3 to 104 +/- 3 ng 24 h-1, NS). By contrast, the high urinary vasopressin excretion and suppressed plasma renin activity found in DOC-treated rats were not altered by Hoe 140.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
651

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amundsen E., Putter J., Friberger P., Knos M., Larsbraten M., Claeson G. Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol. 1979;120A:83–95. doi: 10.1007/978-1-4757-0926-1_9. [DOI] [PubMed] [Google Scholar]
  2. Arbeit L. A., Serra S. R. Decreased total and active urinary kallikrein in normotensive Dahl salt susceptible rats. Kidney Int. 1985 Sep;28(3):440–446. doi: 10.1038/ki.1985.150. [DOI] [PubMed] [Google Scholar]
  3. Bao G., Gohlke P., Qadri F., Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 1992 Jul;20(1):74–79. doi: 10.1161/01.hyp.20.1.74. [DOI] [PubMed] [Google Scholar]
  4. Beierwaltes W. H., Carretero O. A., Scicli A. G. Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol. 1988 Sep;255(3 Pt 2):F408–F414. doi: 10.1152/ajprenal.1988.255.3.F408. [DOI] [PubMed] [Google Scholar]
  5. Berecek K. H., Murray R. D., Gross F., Brody M. J. Vasopressin and vascular reactivity in the development of DOCA hypertension in rats with hereditary diabetes insipidus. Hypertension. 1982 Jan-Feb;4(1):3–12. doi: 10.1161/01.hyp.4.1.3. [DOI] [PubMed] [Google Scholar]
  6. Berry T. D., Hasstedt S. J., Hunt S. C., Wu L. L., Smith J. B., Ash K. O., Kuida H., Williams R. R. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989 Jan;13(1):3–8. doi: 10.1161/01.hyp.13.1.3. [DOI] [PubMed] [Google Scholar]
  7. Biglieri E. G. Spectrum of mineralocorticoid hypertension. Hypertension. 1991 Feb;17(2):251–261. doi: 10.1161/01.hyp.17.2.251. [DOI] [PubMed] [Google Scholar]
  8. Fejes-Tóth G., Zahajszky T., Filep J. Effect of vasopressin on renal kallikrein excretion. Am J Physiol. 1980 Oct;239(4):F388–F392. doi: 10.1152/ajprenal.1980.239.4.F388. [DOI] [PubMed] [Google Scholar]
  9. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T. Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol. 1990 Nov;101(3):632–639. doi: 10.1111/j.1476-5381.1990.tb14132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Griesbacher T., Lembeck F., Saria A. Effects of the bradykinin antagonist B4310 on smooth muscles and blood pressure in the rat, and its enzymatic degradation. Br J Pharmacol. 1989 Mar;96(3):531–538. doi: 10.1111/j.1476-5381.1989.tb11850.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hock F. J., Wirth K., Albus U., Linz W., Gerhards H. J., Wiemer G., Henke S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102(3):769–773. doi: 10.1111/j.1476-5381.1991.tb12248.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Holland O. B., Chud J. M., Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest. 1980 Feb;65(2):347–356. doi: 10.1172/JCI109678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Keiser H. R., Geller R. G., Margolius H. S., Pisano J. J. Urinary kallikrein in hypertensive animal models. Fed Proc. 1976 Feb;35(2):199–202. [PubMed] [Google Scholar]
  14. Lembeck F., Griesbacher T., Eckhardt M., Henke S., Breipohl G., Knolle J. New, long-acting, potent bradykinin antagonists. Br J Pharmacol. 1991 Feb;102(2):297–304. doi: 10.1111/j.1476-5381.1991.tb12169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Madeddu P., Anania V., Parpaglia P. P., Demontis M. P., Varoni M. V., Pisanu G., Troffa C., Tonolo G., Glorioso N. Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats. Br J Pharmacol. 1992 Jun;106(2):380–386. doi: 10.1111/j.1476-5381.1992.tb14344.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Majima M., Katori M., Hanazuka M., Mizogami S., Nakano T., Nakao Y., Mikami R., Uryu H., Okamura R., Mohsin S. S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension. 1991 Jun;17(6 Pt 1):806–813. doi: 10.1161/01.hyp.17.6.806. [DOI] [PubMed] [Google Scholar]
  17. Margolius H. S., Geller R., De Jong W., Pisano J. J., Sjoerdsma A. Altered urinary kallikrein excretion in rats with hypertension. Circ Res. 1972 Mar;30(3):358–362. [PubMed] [Google Scholar]
  18. Mindroiu T., Carretero O. A., Scicli A. G. T-kininogen in rat plasma after nephrectomy and other surgical traumas. Agents Actions Suppl. 1987;22:265–276. doi: 10.1007/978-3-0348-9299-5_28. [DOI] [PubMed] [Google Scholar]
  19. Nakagawa M., Stewart J. M., Vavrek R. J., Nasjletti A. Effects of a kinin antagonist on renal function in rats. Am J Physiol. 1990 Mar;258(3 Pt 2):F643–F648. doi: 10.1152/ajprenal.1990.258.3.F643. [DOI] [PubMed] [Google Scholar]
  20. Nolly H., Carretero O. A., Scicli G., Madeddu P., Scicli A. G. A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats. Hypertension. 1990 Oct;16(4):436–440. doi: 10.1161/01.hyp.16.4.436. [DOI] [PubMed] [Google Scholar]
  21. Okamoto H., Greenbaum L. M. Pharmacological properties of T-kinin (isoleucyl-seryl-bradykinin) from rat plasma. Biochem Pharmacol. 1983 Sep 1;32(17):2637–2638. doi: 10.1016/0006-2952(83)90039-4. [DOI] [PubMed] [Google Scholar]
  22. Pravenec M., Kren V., Kunes J., Scicli A. G., Carretero O. A., Simonet L., Kurtz T. W. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension. 1991 Feb;17(2):242–246. doi: 10.1161/01.hyp.17.2.242. [DOI] [PubMed] [Google Scholar]
  23. Rhaleb N. E., Télémaque S., Rouissi N., Dion S., Jukic D., Drapeau G., Regoli D. Structure-activity studies of bradykinin and related peptides. B2-receptor antagonists. Hypertension. 1991 Jan;17(1):107–115. doi: 10.1161/01.hyp.17.1.107. [DOI] [PubMed] [Google Scholar]
  24. Tausch A., Stegner H., Leake R. D., Artman H. G., Fisher D. A. Radioimmunoassay of arginine vasopressin in urine: development and application. J Clin Endocrinol Metab. 1983 Oct;57(4):777–781. doi: 10.1210/jcem-57-4-777. [DOI] [PubMed] [Google Scholar]
  25. Tomita K., Pisano J. J., Knepper M. A. Control of sodium and potassium transport in the cortical collecting duct of the rat. Effects of bradykinin, vasopressin, and deoxycorticosterone. J Clin Invest. 1985 Jul;76(1):132–136. doi: 10.1172/JCI111935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vanhoutte P. M. Endothelium and control of vascular function. State of the Art lecture. Hypertension. 1989 Jun;13(6 Pt 2):658–667. doi: 10.1161/01.hyp.13.6.658. [DOI] [PubMed] [Google Scholar]
  27. Vavrek R. J., Stewart J. M. Competitive antagonists of bradykinin. Peptides. 1985 Mar-Apr;6(2):161–164. doi: 10.1016/0196-9781(85)90033-6. [DOI] [PubMed] [Google Scholar]
  28. Wiemer G., Wirth K. Production of cyclic GMP via activation of B1 and B2 kinin receptors in cultured bovine aortic endothelial cells. J Pharmacol Exp Ther. 1992 Aug;262(2):729–733. [PubMed] [Google Scholar]
  29. Wirth K., Hock F. J., Albus U., Linz W., Alpermann H. G., Anagnostopoulos H., Henk S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991 Mar;102(3):774–777. doi: 10.1111/j.1476-5381.1991.tb12249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES